SCHEDULE 13G/A: Zentree Investments and Richard Magides Disclose 8.4% Stake in 23andMe Holding Co.

Zentree Investments Limited and Richard Magides have reported a combined beneficial ownership of 8.4% of 23andMe Holding Co.'s Class A Common Stock as of December 31, 2024.

Summary

• Zentree Investments Limited (Cayman Islands) and Richard Magides (United Kingdom) are the reporting persons.
• The filing pertains to Class A Common Stock, par value $0.0001 per share, of 23andMe Holding Co.
• As of December 31, 2024, the reporting persons beneficially owned an aggregate of 1,658,348 shares of Class A Common Stock.
• This beneficial ownership represents 8.4% of the total outstanding Class A Common Stock.
• Of the total, Zentree Investments Limited owns 120,000 shares, and Richard Magides owns 1,538,348 shares.
• Richard Magides is a director of Zentree Investments Limited and is deemed to have shared voting and investment discretion over the securities owned by Zentree.
• The percentage of class was calculated based on 19,640,404 shares of Class A Common Stock outstanding as of December 31, 2024, as reported in 23andMe Holding Co.'s Form 8-K filed on January 28, 2025.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership, indicating a significant stake by an institutional investor and an individual, which can be viewed as a neutral to slightly positive signal of investor confidence in 23andMe Holding Co.

Positives

• A significant beneficial ownership stake of 8.4% in 23andMe Holding Co. has been disclosed by Zentree Investments Limited and Richard Magides.
• The filing indicates that the stake was not acquired for the purpose of changing or influencing control, suggesting a passive investment intent.

Negatives

• No specific negatives regarding the issuer's performance or outlook are disclosed in this ownership filing.

Risks

• This filing, a Schedule 13G, does not contain information regarding the risks associated with 23andMe Holding Co.'s operations or financial health.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding 23andMe Holding Co.'s future outlook.

Industry Context

This filing indicates a significant investment by Zentree Investments Limited and Richard Magides in 23andMe Holding Co., a company operating in the personal genomics and biotechnology sector. Such an investment signals investor interest in the long-term prospects of companies leveraging genetic data for health and research, a growing area within the broader healthcare and technology industries.

Comparison to Industry Standards

• This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information suitable for comparison to industry-specific operational or financial benchmarks.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes, potentially signaling investor confidence.
• Company: A large, passive stake by an investor could provide stability and long-term interest in the company's performance.

Next Steps

• This filing does not outline specific future actions or milestones for 23andMe Holding Co. or the reporting persons beyond the ongoing ownership.

Key Dates

Keywords

23andMe Holding Co., Class A Common Stock, Beneficial Ownership, Schedule 13G, Zentree Investments Limited, Richard Magides, SEC Filing, Equity Stake, Genetics Company, Biotechnology